» Articles » PMID: 32165494

The Cytochrome P450 Enzyme CYP24A1 Increases Proliferation of Mutant KRAS-dependent Lung Adenocarcinoma Independent of Its Catalytic Activity

Overview
Journal J Biol Chem
Specialty Biochemistry
Date 2020 Mar 14
PMID 32165494
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

We previously reported that overexpression of cytochrome P450 family 24 subfamily A member 1 (CYP24A1) increases lung cancer cell proliferation by activating RAS signaling and that CYP24A1 knockdown inhibits tumor growth. However, the mechanism of CYP24A1-mediated cancer cell proliferation remains unclear. Here, we conducted cell synchronization and biochemical experiments in lung adenocarcinoma cells, revealing a link between CYP24A1 and anaphase-promoting complex (APC), a key cell cycle regulator. We demonstrate that CYP24A1 expression is cell cycle-dependent; it was higher in the G-M phase and diminished upon G entry. CYP24A1 has a functional destruction box (D-box) motif that allows binding with two APC adaptors, CDC20-homologue 1 (CDH1) and cell division cycle 20 (CDC20). Unlike other APC substrates, however, CYP24A1 acted as a pseudo-substrate, inhibiting CDH1 activity and promoting mitotic progression. Conversely, overexpression of a CYP24A1 D-box mutant compromised CDH1 binding, allowing CDH1 hyperactivation, thereby hastening degradation of its substrates cyclin B1 and CDC20, and accumulation of the CDC20 substrate p21, prolonging mitotic exit. These activities also occurred with a CYP24A1 isoform 2 lacking the catalytic cysteine (Cys-462), suggesting that CYP24A1's oncogenic potential is independent of its catalytic activity. CYP24A1 degradation reduced clonogenic survival of mutant -driven lung cancer cells, and calcitriol treatment increased CYP24A1 levels and tumor burden in mice. These results disclose a catalytic activity-independent growth-promoting role of CYP24A1 in mutant -driven lung cancer. This suggests that CYP24A1 could be therapeutically targeted in lung cancers in which its expression is high.

Citing Articles

Characterization of Infiltrating Immune Cells and Secretory or Membrane-Associated Proteins in KRAS Lung Adenocarcinoma.

Bian Y, Bi G, Shan G, Liang J, Sui Q, Hu Z J Immunol Res. 2023; 2023:4987832.

PMID: 36793588 PMC: 9925262. DOI: 10.1155/2023/4987832.


Circular RNA Circ_0005962 Contributes to Lung Adenocarcinoma Cell Proliferation and Stem Cell Formation Through Sponging of miR-3611 and Modulating CYP24A1 Expression.

Lu W, Yu Z, Liu J, Li L, Liu L, Li X Biochem Genet. 2022; 61(4):1242-1264.

PMID: 36542209 DOI: 10.1007/s10528-022-10312-6.

References
1.
Mimori K, Tanaka Y, Yoshinaga K, Masuda T, Yamashita K, Okamoto M . Clinical significance of the overexpression of the candidate oncogene CYP24 in esophageal cancer. Ann Oncol. 2004; 15(2):236-41. DOI: 10.1093/annonc/mdh056. View

2.
Rodriguez M, Potter D . CYP1A1 regulates breast cancer proliferation and survival. Mol Cancer Res. 2013; 11(7):780-92. PMC: 3720830. DOI: 10.1158/1541-7786.MCR-12-0675. View

3.
Ramnath N, Daignault-Newton S, Dy G, Muindi J, Adjei A, Elingrod V . A phase I/II pharmacokinetic and pharmacogenomic study of calcitriol in combination with cisplatin and docetaxel in advanced non-small-cell lung cancer. Cancer Chemother Pharmacol. 2013; 71(5):1173-82. PMC: 3637851. DOI: 10.1007/s00280-013-2109-x. View

4.
Zhang Q, Kanterewicz B, Shoemaker S, Hu Q, Liu S, Atwood K . Differential response to 1α,25-dihydroxyvitamin D3 (1α,25(OH)2D3) in non-small cell lung cancer cells with distinct oncogene mutations. J Steroid Biochem Mol Biol. 2012; 136:264-70. PMC: 3674199. DOI: 10.1016/j.jsbmb.2012.09.022. View

5.
Shiratsuchi H, Wang Z, Chen G, Ray P, Lin J, Zhang Z . Oncogenic Potential of CYP24A1 in Lung Adenocarcinoma. J Thorac Oncol. 2016; 12(2):269-280. DOI: 10.1016/j.jtho.2016.10.010. View